We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
Read MoreHide Full Article
Key Takeaways
UnitedHealth stands out with its integrated Optum platform, driving stable growth and margins.
UNH guides for 2026 membership decline to boost profitability amid rising medical costs.
Elevance expands Carelon services but faces margin pressure and a weaker earnings outlook.
UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) are two of the largest players in the U.S. managed care space, operating at a time when rising medical costs, shifting reimbursement structures and growing demand for integrated care are redefining industry dynamics. Both companies offer diversified exposure across insurance and healthcare services, making them central to how the sector adapts to cost pressures and evolving care models.
Despite these similarities, their strategic positioning differs in meaningful ways. UnitedHealth has built a deeply integrated ecosystem through its Optum platform, emphasizing care delivery and data-led services, while Elevance remains more anchored in its core insurance business with a gradual expansion into services. These differences influence how each company approaches growth, cost management and earnings diversification in a changing healthcare landscape. Also, improving policy visibility is acting as a tailwind, with the Centers for Medicare and Medicaid Services finalizing Medicare Advantage payment rates for 2027 at an average increase of 2.48%, significantly higher than the earlier 0.09% proposal in January, thereby strengthening sector sentiment and revenue outlook.
Let’s dive deep and closely compare the fundamentals to determine which stock offers greater upside right now.
The Case for UnitedHealth
UnitedHealth’s strength lies in its deeply integrated model, where insurance and healthcare services operate in tandem. Through its Optum segment, the company has built a high-margin services engine that spans pharmacy benefit management, care delivery and data analytics. This vertical integration not only enhances profitability but also creates a buffer against rising medical costs, allowing UnitedHealth to maintain earnings stability even when insurance margins tighten. The company’s total revenues rose 12.3% year over year in the fourth quarter of 2025, with 17.5% growth at UnitedHealthcare and 8% growth at Optum.
A key strategic shift is the company’s willingness to accept membership contraction to restore margins. UnitedHealth is guiding for a notable decline in Medicare Advantage and overall membership in 2026, driven by deliberate product repositioning and pricing actions. This signals a pivot toward profitability and sustainability over short-term enrollment gains. It expects medical memberships to be in the range of 46.945-47.495 million in 2026, with significant declines in commercial risk and Medicaid heads.
UnitedHealth’s scale provides a significant competitive advantage. Its ability to negotiate provider rates, invest in technology and expand care delivery infrastructure reinforces its leadership position. While membership growth may moderate in the near term, the company’s earnings power remains anchored in its diversified revenue streams and operational efficiency, making it a relatively defensive play in the sector.
Financially, UNH is in a solid position. It ended 2025 with $28.1 billion in cash and short-term investments, sufficient to cover its short-term borrowings and current maturities of long-term debt, which stands at $6.1 billion. Its total debt-to-capital of 41.95% is below ELV’s 42.01% and the industry’s 44.04%. The company also rewarded more than $13 billion to its shareholders in the form of share repurchases and dividends during 2025. UNH missed earnings estimates twice in the past four quarters and beat on the other occasions.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
Elevance’s positioning is supported by a diversified healthcare platform and a strategy centered on improving care affordability and outcomes. The company continues to build capabilities around whole-person health, integrating medical, pharmacy and behavioral services to enhance care coordination and member experience. This approach is gaining traction with employers and government programs, reinforcing its relevance in an increasingly complex healthcare landscape.
The company is actively reshaping its portfolio with a clear focus on sustainability. Across Medicare Advantage, Medicaid and ACA markets, Elevance is taking deliberate actions to refine its product mix, emphasizing segments that align with long-term margin and performance objectives. This repositioning reflects a measured approach to reducing volatility and improving the consistency of earnings.
Another key aspect of Elevance’s strategy is its ongoing transformation into a broader healthcare platform. Through its Carelon segment, the company is investing in services such as pharmacy, behavioral health and care management. Although still in a scaling phase compared to UNH’s Optum, Carelon represents a strategic pivot toward higher-value, service-driven revenue streams that could enhance profitability over time. ELV’s total revenues rose 9.5% year over year in the fourth quarter of 2025, along with 27% growth in operating revenues for Carelon. It beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 7.9%.
Elevance Health, Inc. Price, Consensus and EPS Surprise
ELV exited the fourth quarter of 2025 with a solid liquidity position, holding $9.5 billion in cash and cash equivalents. The company also demonstrates relatively stronger capital efficiency, with a return on invested capital of 8.3%, notably higher than UnitedHealth at 5.4%. In 2025, Elevance returned $4.1 billion to its shareholders through repurchases and dividends. Its dividend yield of 2.2% is lower than that of UNH’s 2.8%.
How Do the Estimates Compare for UNH & ELV?
The Zacks Consensus Estimate favors UNH at this stage. The consensus estimate for UNH’s 2026 earnings indicates an 8% increase from a year ago. Meanwhile, the consensus estimate for revenues suggests a 1.6% decline. On the other hand, the consensus estimate for ELV’s 2026 earnings indicates a 14.4% decline from a year ago, while the same for revenues suggests a 1.4% decline.
Valuation: UNH vs. ELV
Coming to the valuation story, it seems that investors are willing to pay a premium for UnitedHealth compared to Elevance. This is reflected in UNH’s forward 12-month price/earnings (P/E) of 17.16X compared with ELV’s 11.66X. Both are currently trading below their five-year median P/E value.
Image Source: Zacks Investment Research
Price Performance Comparison
In the year-to-date period, UnitedHealth has shed less value than Elevance. However, the S&P 500 has increased 1.9% during this time.
YTD Price Performance – UNH, ELV & S&P 500
Image Source: Zacks Investment Research
Conclusion
UnitedHealth and Elevance are both navigating a complex healthcare environment marked by elevated cost trends and shifting policy dynamics. While ELV is focused on execution, portfolio refinement and building out its Carelon platform, its near term outlook remains constrained by margin pressure in Medicaid and a reset in earnings expectations.
In contrast, UNH appears better positioned to deliver more stable and durable growth, supported by its scale, diversified revenue streams and the strength of its Optum platform. Its ability to balance margin recovery with operational efficiency and capital strength provides greater visibility into earnings. As a result, UNH currently stands out as the relatively stronger play for investors seeking resilience and long-term upside in the managed care space.
While UnitedHealth currently carries a Zacks Rank #3 (Hold), Elevance has a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) and Elevance Health, Inc. (ELV - Free Report) are two of the largest players in the U.S. managed care space, operating at a time when rising medical costs, shifting reimbursement structures and growing demand for integrated care are redefining industry dynamics. Both companies offer diversified exposure across insurance and healthcare services, making them central to how the sector adapts to cost pressures and evolving care models.
Despite these similarities, their strategic positioning differs in meaningful ways. UnitedHealth has built a deeply integrated ecosystem through its Optum platform, emphasizing care delivery and data-led services, while Elevance remains more anchored in its core insurance business with a gradual expansion into services. These differences influence how each company approaches growth, cost management and earnings diversification in a changing healthcare landscape. Also, improving policy visibility is acting as a tailwind, with the Centers for Medicare and Medicaid Services finalizing Medicare Advantage payment rates for 2027 at an average increase of 2.48%, significantly higher than the earlier 0.09% proposal in January, thereby strengthening sector sentiment and revenue outlook.
Let’s dive deep and closely compare the fundamentals to determine which stock offers greater upside right now.
The Case for UnitedHealth
UnitedHealth’s strength lies in its deeply integrated model, where insurance and healthcare services operate in tandem. Through its Optum segment, the company has built a high-margin services engine that spans pharmacy benefit management, care delivery and data analytics. This vertical integration not only enhances profitability but also creates a buffer against rising medical costs, allowing UnitedHealth to maintain earnings stability even when insurance margins tighten. The company’s total revenues rose 12.3% year over year in the fourth quarter of 2025, with 17.5% growth at UnitedHealthcare and 8% growth at Optum.
A key strategic shift is the company’s willingness to accept membership contraction to restore margins. UnitedHealth is guiding for a notable decline in Medicare Advantage and overall membership in 2026, driven by deliberate product repositioning and pricing actions. This signals a pivot toward profitability and sustainability over short-term enrollment gains. It expects medical memberships to be in the range of 46.945-47.495 million in 2026, with significant declines in commercial risk and Medicaid heads.
UnitedHealth’s scale provides a significant competitive advantage. Its ability to negotiate provider rates, invest in technology and expand care delivery infrastructure reinforces its leadership position. While membership growth may moderate in the near term, the company’s earnings power remains anchored in its diversified revenue streams and operational efficiency, making it a relatively defensive play in the sector.
Financially, UNH is in a solid position. It ended 2025 with $28.1 billion in cash and short-term investments, sufficient to cover its short-term borrowings and current maturities of long-term debt, which stands at $6.1 billion. Its total debt-to-capital of 41.95% is below ELV’s 42.01% and the industry’s 44.04%. The company also rewarded more than $13 billion to its shareholders in the form of share repurchases and dividends during 2025. UNH missed earnings estimates twice in the past four quarters and beat on the other occasions.
UnitedHealth Group Incorporated Price, Consensus and EPS Surprise
UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote
The Case for Elevance
Elevance’s positioning is supported by a diversified healthcare platform and a strategy centered on improving care affordability and outcomes. The company continues to build capabilities around whole-person health, integrating medical, pharmacy and behavioral services to enhance care coordination and member experience. This approach is gaining traction with employers and government programs, reinforcing its relevance in an increasingly complex healthcare landscape.
The company is actively reshaping its portfolio with a clear focus on sustainability. Across Medicare Advantage, Medicaid and ACA markets, Elevance is taking deliberate actions to refine its product mix, emphasizing segments that align with long-term margin and performance objectives. This repositioning reflects a measured approach to reducing volatility and improving the consistency of earnings.
Another key aspect of Elevance’s strategy is its ongoing transformation into a broader healthcare platform. Through its Carelon segment, the company is investing in services such as pharmacy, behavioral health and care management. Although still in a scaling phase compared to UNH’s Optum, Carelon represents a strategic pivot toward higher-value, service-driven revenue streams that could enhance profitability over time. ELV’s total revenues rose 9.5% year over year in the fourth quarter of 2025, along with 27% growth in operating revenues for Carelon. It beat earnings estimates in three of the past four quarters and missed once, with an average surprise of 7.9%.
Elevance Health, Inc. Price, Consensus and EPS Surprise
Elevance Health, Inc. price-consensus-eps-surprise-chart | Elevance Health, Inc. Quote
ELV exited the fourth quarter of 2025 with a solid liquidity position, holding $9.5 billion in cash and cash equivalents. The company also demonstrates relatively stronger capital efficiency, with a return on invested capital of 8.3%, notably higher than UnitedHealth at 5.4%. In 2025, Elevance returned $4.1 billion to its shareholders through repurchases and dividends. Its dividend yield of 2.2% is lower than that of UNH’s 2.8%.
How Do the Estimates Compare for UNH & ELV?
The Zacks Consensus Estimate favors UNH at this stage. The consensus estimate for UNH’s 2026 earnings indicates an 8% increase from a year ago. Meanwhile, the consensus estimate for revenues suggests a 1.6% decline. On the other hand, the consensus estimate for ELV’s 2026 earnings indicates a 14.4% decline from a year ago, while the same for revenues suggests a 1.4% decline.
Valuation: UNH vs. ELV
Coming to the valuation story, it seems that investors are willing to pay a premium for UnitedHealth compared to Elevance. This is reflected in UNH’s forward 12-month price/earnings (P/E) of 17.16X compared with ELV’s 11.66X. Both are currently trading below their five-year median P/E value.
Image Source: Zacks Investment Research
Price Performance Comparison
In the year-to-date period, UnitedHealth has shed less value than Elevance. However, the S&P 500 has increased 1.9% during this time.
YTD Price Performance – UNH, ELV & S&P 500
Image Source: Zacks Investment Research
Conclusion
UnitedHealth and Elevance are both navigating a complex healthcare environment marked by elevated cost trends and shifting policy dynamics. While ELV is focused on execution, portfolio refinement and building out its Carelon platform, its near term outlook remains constrained by margin pressure in Medicaid and a reset in earnings expectations.
In contrast, UNH appears better positioned to deliver more stable and durable growth, supported by its scale, diversified revenue streams and the strength of its Optum platform. Its ability to balance margin recovery with operational efficiency and capital strength provides greater visibility into earnings. As a result, UNH currently stands out as the relatively stronger play for investors seeking resilience and long-term upside in the managed care space.
While UnitedHealth currently carries a Zacks Rank #3 (Hold), Elevance has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.